ImmuPharma plc (LON:IMM – Get Free Report)’s stock price traded up 12% during trading on Wednesday . The stock traded as high as GBX 10.80 and last traded at GBX 10.38. 6,711,875 shares were traded during mid-day trading, a decline of 17% from the average session volume of 8,070,593 shares. The stock had previously closed at GBX 9.26.
ImmuPharma Stock Up 13.4%
The stock has a market cap of £52.79 million, a PE ratio of -11.80 and a beta of 1.53. The firm has a fifty day moving average of GBX 10.98 and a 200 day moving average of GBX 5.43.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- Buy P&G Now, Before It Sets A New All-Time High
- Papa John’s $2.7 Billion Takeover Bid: A Price on Untapped Value
- What is the S&P 500 and How It is Distinct from Other Indexes
- Is Qualcomm Up 40% or Down 20%? 2 Contrarian Takes
- What is the NASDAQ Stock Exchange?
- Guardian Pharmacy Stock Pops on Q3 Strength and Upbeat Forecast
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
